Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 09 tags : Therapy save search
Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 0.0%
H: 9.13%
C: 6.25%
ongoing gene therapies phase 1 gene therapy therapy aav9
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.61%
H: 0.29%
C: -5.25%
fda heart therapy breakthrough therapy granted grant designation
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Metastatic Urothelial Cancer
Published: 2021-09-09 (Crawled : 13:15) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.74%
H: 0.49%
C: -1.33%
immunotherapy therapy collaboration cancer trial nivolumab
Cryopreservation: A Key Element in the Successful Delivery of GMP Cell Therapies
Published: 2021-09-09 (Crawled : 13:00) - thermogenesis.com
THMO | $0.6695 3.0% 2.91% 8.6K
|
Health Technology
|
| O: -0.84%
H: 4.24%
C: -2.12%
cryo liver therapy
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
BHVN 1 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -0.14%
H: 2.85%
C: -0.58%
treatment europe migraine therapy
BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
Published: 2021-09-09 (Crawled : 12:00) - globenewswire.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 3.74%
H: 7.88%
C: 1.89%
presentation europe therapy
Where AI and Immunotherapy Converge to Reprogram Immunity
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.54%
H: 0.23%
C: -0.59%
immunotherapy therapy
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 0.79%
H: 6.36%
C: 1.1%
collaboration license arcus therapy bioscience
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.